Glenmark reports net profit at Rs 234 crore in Q2
New Delhi: Drug firm Glenmark Pharmaceuticals on Friday reported a consolidated net profit of Rs 233.99 crore for the second quarter ended September 30.
The company had posted a net profit of Rs 255.54 crore for the same period previous fiscal, Glenmark said in a BSE filing.
Its consolidated revenue stood at Rs 2,952.47 crore for the quarter under consideration. It was Rs 2,815.04 crore for the same period a year ago, it added.
"The net profit is not comparable on account of forex gain recorded in the previous corresponding quarter of the financial year 19-20," Glenmark said in the regulatory filing.
Commenting on the results, Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said: "Our relentless focus on costs and new product introductions during these challenging times have helped increase revenue and operating profit in the second quarter of this financial year".
India and active pharmaceutical ingredient (API) business performed well along with the Europe and ROW region, he added.
Read also: Glenmark gets USFDA nod to generic version of Rapamune
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.